Stock Report

All about this stock under one free report Last Updated: 23-Sep-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Syschem (India) Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

BSE: 531173

₹31.74

up-down-arrow ₹1.94 (6.51%)

As on 23-Sep-2026 12:54IST

Market cap

info icon

₹170 Cr

Revenue (TTM)

info icon

₹654 Cr

P/E Ratio

info icon

27.7

P/B Ratio

info icon

1.2

Div. Yield

info icon

0 %

Edit peer-selector-edit
Syschem (India) Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Market cap (₹ Cr)
 170 37,373 28,790 17,017 15,944
Revenue (₹ Cr)
 654 9,683 2,372 2,590 1,108
Net Profit (₹ Cr)
 6.15 1,018.97 497.77 603.02 270.18
Net Margin (%)
 0.94 10.47 20.72 22.63 23.29
RoE (%)
 5.66 21.30 28.49 19.61 14.45
Price to Earnings
 27.68 36.95 57.84 28.22 57.90
Price-To-Book
 1.20 7.15 14.24 4.88 7.69

Income Statement (₹ Cr)

Syschem (India) Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Operating Revenue arrow
653.82 9,683.45 2,371.81 2,590.40 1,108.39
Total Income arrow
653.88 9,730.84 2,402.61 2,664.23 1,159.90
Total Expenditure arrow
634.64 7,739.53 1,608.91 1,753.71 720.01
EBITDA arrow
19.17 1,943.92 762.90 836.69 388.38
Depreciation arrow
4.86 425.10 98.11 78.88 74.78
EBIT arrow
14.31 1,518.82 664.79 757.81 313.60
Interest arrow
2.72 148.45 26.33 5.43 0.26
Other Income arrow
0.06 47.39 30.80 73.83 51.50
Exceptional Items arrow
0.00 -27.85 0.00 -25.66 -3.28
Profit before Tax arrow
11.66 1,389.91 669.26 800.55 361.56
Provision for Tax arrow
5.52 370.94 171.48 197.53 91.39
Profit after Tax arrow
6.15 1,018.97 497.77 603.02 270.18

Liabilities (₹ Cr)

Syschem (India) Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Shareholder's Funds arrow
122.43 4,950.03 1,874.47 3,332.13 2,017.06
Minority Interest arrow
0.00 -7.58 0.00 0.00 2.51
Non-Current Liabilities arrow
6.29 723.57 345.47 142.73 50.51
Current Liabilities arrow
163.03 3,912.24 710.20 508.04 169.08
Total Liabilities arrow
217.26 8,121.73 2,179.88 3,753.59 2,034.25

Assets (₹ Cr)

Syschem (India) Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Non-Current Assets arrow
67.60 3,392.16 1,290.62 1,321.38 957.22
Current Assets arrow
218.57 5,612.10 1,483.13 2,649.36 1,250.11
Total Assets arrow
217.26 8,121.73 2,179.88 3,753.59 2,034.25
Total Debt* arrow
0.00 731.70 136.01 0.00 0.38
Net Current Assets arrow
55.54 1,699.86 772.93 2,141.33 1,081.04
Contingent Liabilities arrow
50.19 393.94 8.97 4.82 3.91

Cashflow (₹ Cr)

Syschem (India) Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Cash From Operating Activities arrow
-10.09 851.71 317.40 391.52 244.52
Cash Flow from Investing Activities arrow
-21.67 -94.00 -298.16 -615.65 -159.99
Cash from Financing Activities arrow
33.81 -813.96 24.96 -6.23 -98.77
Net Cash Inflow / Outflow arrow
2.04 -56.25 44.21 -230.35 -14.24

Ratios

Profitability Ratios

 Syschem (India) Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
ROCE (%) arrow
1.45 22.49 23.45 25.50 29.62
ROE (%) arrow
5.66 21.30 28.49 19.61 14.45
ROA (%) arrow
2.41 11.42 19.48 16.31 12.66
EBIT Margin (%) arrow
2.19 15.68 28.03 29.25 28.29
Net Margin (%) arrow
0.94 10.47 20.72 22.63 23.29
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Syschem (India) Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Revenue Growth (%) arrow
59.14 18.36 78.33 7.93 -6.72
EBIT Growth (%) arrow
448.18 30.43 303.07 19.88 -26.64
Net Profit Growth (%) arrow
208.02 32.39 182.61 21.66 -24.38
EPS Growth (%) arrow
209.93 36.68 277.72 25.42 -21.99
Book Value Growth (%) arrow
32.21 50.94 18.89 20.94 18.74

Valuation Ratios

 Syschem (India) Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Price / Earnings arrow
21.10 36.29 58.07 27.11 57.64
Price / Book Value arrow
1.12 7.17 14.30 4.84 7.72
Dividend Yield (%) arrow
0.00 0.18 0.15 0.36 0.49
EV/EBITDA arrow
8.22 19.82 37.68 19.24 40.16
Market Cap (₹ Cr) arrow
159.07 20,327.45 15,494.53 13,228.83 17,537.35

Solvency Ratios

 Syschem (India) Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debt to Equity arrow
0.00 0.05 0.09 0.00 0.00
Short term debt to equity ratio arrow
-- 0.11 -- -- 0.00
Current Ratio arrow
1.34 1.43 2.09 5.21 7.39
Quick Ratio arrow
0.98 0.82 1.37 3.85 5.46
Interest Coverage arrow
5.30 10.36 26.41 148.49 1,386.30

Operating Efficiency Ratios

 Syschem (India) Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debtors to sales (%) arrow
22.10 26.46 22.82 41.42 41.52
Asset Turnover arrow
2.57 1.09 0.93 0.70 0.52
Receivable days arrow
74.65 87.83 85.17 132.12 132.49
Inventory Days arrow
56.55 78.64 90.97 102.08 68.07
Payable days arrow
128.37 174.97 137.94 133.54 123.94
Cash Conversion Cycle arrow
2.82 -8.50 38.21 100.66 76.63
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...